Raluca Budiu-Predoiu
Director, Precision Medicine Abbvie
Experienced and successful leader of precision medicine in early and late stages of clinical development, across multiple treatment modalities (small molecules, ADCs, monoclonal antibodies, CAR-T cells and vaccines) and therapeutic areas (oncology, immune-oncology, autoimmunity). Expertise in implementing global companion diagnostics for patient selection across the continuum of drug development. Recognized leader in the clinical biomarker space, successfully integrating pre-clinical and clinical biomarker work to inform on dose selection, drug combinations, indications selection for first in human studies, patient selection and differentiation from competitors.
Seminars
Wednesday 22nd July 2026
Panel Discussion: Leveraging Methylation-Based Liquid Biopsies to Deliver Earlier, More Actionable Trial Signals
9:30 am
- Where can methylation-based liquid biopsy create tangible impact in drug development today?
- Can methylation enable earlier and more confident clinical trial decision-making?
- What must happen for methylation to become embedded in mainstream clinical trial design?
Moderated by:
Tuesday 21st July 2026
Building the ctDNA Blueprint: A Cross-Functional Strategy to Advance Oncology Drug Development
10:30 am
- ctDNA as a predictive marker for therapeutic response and a potential surrogate for survival outcomes, enabling faster, more efficient trial designs
- ctDNA as an early, sensitive marker for tracking tumor burden and minimal residual disease (MRD), allowing for earlier intervention and better monitoring of disease progression
- Longitudinal ctDNA analysis for determining biologically active dosages, allowing for adjustments in dosage regimens to maximize efficacy while minimizing toxicity
